Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2971665 | 0.74 | ADRA2A (0.37) | HTTALDH1A1L3MBTL1 | |
| SCHEMBL2967279 | 0.70 | ADRA2A (0.34) | SMN1; SMN2ALDH1A1L3MBTL1GAA | |
| SCHEMBL2958324 | 0.64 | CHEK2 (0.39) | ALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL17430265 | 0.62 | CHEK2 (0.40) | KMT2AL3MBTL1 | |
| SCHEMBL5846216 | 0.60 | CHEK2 (0.36) | KMT2AL3MBTL1 | |
| SCHEMBL7409567 | 0.60 | IDO1 (0.70) | IDO1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2932575 | 0.59 | IDO1 (0.70) | IDO1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL25931026 | 0.59 | SRD5A1 (0.42) | SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL2794062 | 0.58 | IDO1 (1.00) | IDO1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2794995 | 0.57 | IDO1 (1.00) | IDO1HTTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237091-A1 | A SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2023081514-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2022094132-A1 | A SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-05 | — | — | WO | claimed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4237091-A1 | A SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4045054-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | The Regents of the University of California (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022125553-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022094132-A1 | A SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-05 | — | — | WO | disclosed |